Morningside Venture Partners
VC Fund
New York, United States
Morningside Venture Partners is a VC fund in New York focused on Biotechnology and Health Care. Morningside Venture Partners focuses on partnering with talented entrepreneurs to develop the next wave of truly great companies. Their team is comprised of a carefully curated group of angel investors from investment banking and management consulting platforms worldwide.
- Total investments:
- 38
- Last investment:
- Lead investor:
- 24%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Morningside Venture Partners invests in
Stages Morningside Venture Partners invests in
Countries Morningside Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $109k–$62M
- Series B
- $10M–$78M
- Series C
- $30M–$100M
Investment Focus
Industry
- Biotechnology 15 (39%)
- Health Care 13 (34%)
- Medical 8 (21%)
- Therapeutics 6 (16%)
- Software 4 (11%)
Stage
- Series B 11 (29%)
- Series A 10 (26%)
- Seed 3 (8%)
- Series C 3 (8%)
- Funding Round 3 (8%)
Country
- United States 15 (39%)
- China 11 (29%)
- United Kingdom 2 (5%)
- France 1 (3%)
- Israel 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dilip Rao
Co-Founder
|
Co-Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AGORA is B2B E-Commerce B2B platform and it has several micro services:- B2B Dealer portal for B2B E-commerce sale- Marketplace B2B for create different business models in any industries.- PIM Product Information Management for management digital products in E-Commerce.Our platform allows any company start business faster than otherplatforms. We use language Python and Low Code approach for launch MVP. AGORA is provided SaaS and OnPremise.All companies tired from long terms of development and low quality. We suggest another approach. We make platform which can develop and start without developers. | $70K / Seed / Oct 17, 2023 | ||
| Otolith Labs has developed a novel wearable medical device that is on track to be the first FDA approved device for the treatment of vertigo through the De Novo process in 2023. The technology provides immediate relief of symptoms in approximately 80% of vertigo cases based on pilot clinical data. Otolith Labs has received $1.8 million in contractsfrom the US Department of Defense to further develop the technology for their personnel needs. | $20M / Series A / Sep 07, 2022 | ||
| Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detectearlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com. | $30M / Series C / Mar 22, 2022 | ||
| CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | Venture - Series Unknown / Jan 26, 2022 | ||
| Casana is unlocking a new category in healthcare technologies that enable effortless, integrated and consistent in-home heart health monitoring. Casana’s first product, The Heart Seat™ is an IoT heart health toilet seat that captures clinically relevant measurements, including heart rate, blood pressure, blood oxygenation, and cardiac output.Casana’s mission is to assist medical teams in their care management of patients with chronic conditions beyond the four walls of the hospital, starting with the 6M+ people in the US living with Heart Failure. | $40M / Series B / Jan 21, 2022 | ||
| Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.The company wasfounded in 2018 and is based in Israel, the Netherlands, and Boston. | $43M / Series B / Nov 03, 2021 | ||
| Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential toreprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases. | $78M / Series B / Oct 05, 2021 | ||
| Alyce is an AI-powered platform that works as a door-opener or to continue to develop real sales relationships. The platform redefining direct mail, swag and gifts with its scalable, sustainable, hyper-personalized approach to account-based marketing. It uses personal social data to tell you the perfect gift to give and handles orders, shipping,and reporting for 1-10,000 gifts, and is 100% free.Alyce builds real, personal relationships that deliver up to twice the named account penetration and drives 5x pipeline versus traditional approaches. It makes B2B gift-giving simple, effective and measurable. The company was founded in December of 2015, Alyce is a privately held company headquartered in Boston, MA. | $30M / Series B / Apr 08, 2021 | ||
| Tallac Therapeutics offers next-generation immunotherapies for cancer patients. The company is based in Burlingame, California. | $62M / Series A / Dec 01, 2020 | ||
| Zilliz was founded in 2017 and operates as a distributed team with offices in both the U.S. and China. The company specializes in the development of open-source, AI-powered unstructured data analysis software, and is the initiator and primary contributor to the vector similarity search project Milvus. Milvus was released under an open-sourcelicense in October 2019. It has been “starred” over 4,400 times on GitHub and engaged 120+ contributors. Milvus has been adopted by 400+ enterprise users, with applications spanning image processing, computer vision, natural language processing (NLP), speech recognition, recommendation engines, search engines, new drug development, gene analysis, and more. In April 2020, Milvus became an incubation-stage project at the LF AI & Data Foundation, and currently has more commits than any other project in the incubator. | $43M / Series B / Nov 16, 2020 | ||
| See all 38 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Morningside Venture Partners invest in?
Morningside Venture Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 38 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Morningside Venture Partners's check size?
Morningside Venture Partners typically joins rounds of $109k–$62M at Series A, $10M–$78M at Series B and $30M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Morningside Venture Partners participates in.
How do I contact Morningside Venture Partners?
Public channels for Morningside Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Morningside Venture Partners?
The team at Morningside Venture Partners includes Dilip Rao (Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
